Semaglutide Injection pen Finished Product Manufacturer Bulk supply

Semaglutide is a long-acting GLP-1 receptor agonist that possesses the triple effects of lowering blood sugar, weight loss, and cardiovascular protection. It is currently one of the most widely used drugs for metabolic diseases worldwide.

Approved Indications

1. Type 2 diabetes mellitus
   • Improves glycemic control in adults
   • Reduces cardiovascular risk in patients with established cardiovascular disease
2. Chronic weight management
   • Adults with obesity (BMI ≥ 30 kg/m²)
   • Adults with overweight (BMI ≥ 27 kg/m²) and at least one weight-related comorbidity
3. Oral formulation
   • Glycemic control in adults with type 2 diabetes

Dosage and Administration (Injectable)

• Starting dose: 0.25 mg once weekly for 4 weeks
• Maintenance dose: 0.5 mg once weekly
• Maximum dose: 1 mg once weekly
• Injection sites: Abdomen, thigh, or upper arm

Common Adverse Reactions

• Gastrointestinal: Nausea, vomiting, diarrhea, constipation, abdominal distension
• Hypoglycemia (low risk as monotherapy)
• Headache, fatigue, injection-site reaction

Stability Testing

• Thermal, enzymatic, and oxidative degradation studies

• Shelf-life evaluation & formulation robustness

Formulation Development

• Enhances solubility, bioavailability, and structural integrity

• Tailored for injectable, topical, and research-grade use

Excipient Compatibility Testing

• Evaluates interactions between peptides & inactive components

• Ensures safety, stability, and performance

Protease Resistance Evaluation

• Assesses susceptibility to enzymatic breakdown

• Supports development of more durable peptide products

Encapsulation & Carrier Systems

• Liposomes, microspheres, and other delivery vehicles

• Protects peptides & enables controlled release

Administration Route Assessment

Optimized for:

• Parenteral delivery (injectables)

• Dermal absorption (cosmetic/topical)

• In vitro research applications